LOS CABOS, Mexico & GAITHERSBURG, Md.--(BUSINESS WIRE)--VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus (SIV) achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls. VRX1116 is a simian analogue of VRX1273, the Company’s investigational, lentiviral-based vaccine for HIV. HIV DART brings together the top HIV clinicians, researchers, and basic scientists to discuss the ongoing drug development process in antiretroviral research, providing the scientific community with an increased understanding of the current and future challenges in therapeutics for HIV infection.
